These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23271192)

  • 21. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
    Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.
    Arakawa R; Ito H; Takano A; Okumura M; Takahashi H; Takano H; Okubo Y; Suhara T
    Psychopharmacology (Berl); 2010 May; 209(4):285-90. PubMed ID: 20349050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography.
    Sevy S; Smith GS; Ma Y; Dhawan V; Chaly T; Kingsley PB; Kumra S; Abdelmessih S; Eidelberg D
    Psychopharmacology (Berl); 2008 May; 197(4):549-56. PubMed ID: 18270689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers.
    Kim E; Kwon JS; Shin YW; Lee JS; Kang WJ; Jo HJ; Lee JM; Yu KS; Kang DH; Cho JY; Jang IJ; Shin SG
    Pharmacogenet Genomics; 2008 Feb; 18(2):91-7. PubMed ID: 18192895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats.
    Der-Ghazarian T; Charntikov S; Varela FA; Crawford CA; McDougall SA
    J Neural Transm (Vienna); 2010 May; 117(5):573-83. PubMed ID: 20372943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of aripiprazole and haloperidol on neural activation during the n-back in healthy individuals: A functional MRI study.
    Goozee R; Reinders AATS; Handley R; Marques T; Taylor H; O'Daly O; McQueen G; Hubbard K; Mondelli V; Pariante C; Dazzan P
    Schizophr Res; 2016 Jun; 173(3):174-181. PubMed ID: 25778615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.
    Handley R; Zelaya FO; Reinders AA; Marques TR; Mehta MA; O'Gorman R; Alsop DC; Taylor H; Johnston A; Williams S; McGuire P; Pariante CM; Kapur S; Dazzan P
    Hum Brain Mapp; 2013 Feb; 34(2):272-82. PubMed ID: 22451196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
    Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
    J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration.
    Wee S; Wang Z; Woolverton WL; Pulvirenti L; Koob GF
    Neuropsychopharmacology; 2007 Oct; 32(10):2238-47. PubMed ID: 17327886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
    Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
    Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
    Stahl SM
    J Clin Psychiatry; 2001 Nov; 62(11):841-2. PubMed ID: 11775041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
    Goff DC
    Am J Psychiatry; 2008 Aug; 165(8):940-3. PubMed ID: 18676595
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
    Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
    Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reward motivation in humans and its relationship to dopamine D
    Caravaggio F; Fervaha G; Browne CJ; Gerretsen P; Remington G; Graff-Guerrero A
    J Psychopharmacol; 2018 Mar; 32(3):357-366. PubMed ID: 29442593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.